Illumina (ILMN) to Release Quarterly Earnings on Monday

Illumina (NASDAQ:ILMN) is scheduled to announce its earnings results after the market closes on Monday, November 4th. Analysts expect the company to announce earnings of $0.87 per share for the quarter. Illumina has set its FY 2024 guidance at 3.800-3.950 EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.24. The firm had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The business’s revenue for the quarter was down 5.4% on a year-over-year basis. During the same period last year, the firm earned $0.32 earnings per share. On average, analysts expect Illumina to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Illumina Stock Performance

Shares of Illumina stock opened at $141.95 on Monday. The firm has a fifty day moving average of $134.53 and a two-hundred day moving average of $121.57. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11. The stock has a market capitalization of $22.61 billion, a price-to-earnings ratio of -7.41 and a beta of 1.15. Illumina has a 52 week low of $89.00 and a 52 week high of $151.40.

Analyst Ratings Changes

Several equities analysts have weighed in on ILMN shares. Scotiabank cut their target price on Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research note on Thursday, August 15th. Citigroup boosted their price objective on shares of Illumina from $140.00 to $155.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. StockNews.com assumed coverage on shares of Illumina in a research report on Thursday, August 29th. They issued a “buy” rating for the company. Argus raised Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective on the stock in a research note on Wednesday, August 28th. Finally, Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $154.33.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.